Navigation Links
Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
Date:4/18/2011

NEW YORK, April 18, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced today that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd. (Torii), JT's pharmaceutical business subsidiary, has commenced the Phase 3 clinical program of ferric citrate in Japan for the treatment of patients with hyperphosphatemia.  Under the license agreement with JT/Torii, within 30 days, Keryx will receive a non-refundable milestone payment of $5 million from JT/Torii for the achievement of this milestone.  Zerenex™ (ferric citrate), a ferric iron-based phosphate binder, is also in Phase 3 clinical development in the United States for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis.

Ron Bentsur, Chief Executive Officer of Keryx, stated, "We congratulate our partner, JT/Torii, on the initiation of the Phase 3 program in Japan and are excited by their progress.  We believe that this serves to further validate the commercial potential for Zerenex worldwide."  

Keryx holds a worldwide license (except for certain Asian Pacific countries) to Zerenex from Panion & BF Biotech, Inc.

Sublicense Agreement with Japan Tobacco & Torii PharmaceuticalIn September 2007, Keryx sublicensed to JT and Torii the exclusive rights for the development and commercialization of its hyperphosphatemia drug, Zerenex (ferric citrate), in Japan. The licensing arrangement calls for JT and Torii to pay to Keryx up to $100 million in up-front license fees and payments upon the achievement of specified milestones, of which $28 million has been received by Keryx to date.  In addition, upon commercialization, JT and Torii will make royalty payments to Keryx on net sales of the drug in Japan. JT and Torii are responsible for all development and commercialization costs in Japan.  

About Keryx Biopharmaceuticals, Inc.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with approved therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex™ (ferric citrate) may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website and the FDA website is not incorporated by reference into this press release and is included for reference purposes only. KERYX CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail: lfischer@keryx.com
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
4. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
5. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
7. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
8. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
9. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
10. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
11. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016  Balloon catheter is ... which is inserted into the femoral artery in the ... arm to treat constricted blood vessels. These products are ... to atherosclerosis – deposition of lipid substances in the ... catheter market is projected to expand at a CAGR ...
(Date:12/5/2016)... , Dec. 5, 2016 Spain Glaucoma Surgery ... new report, "Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices market. The report provides value, in millions ... (USD) within market segements - Canaloplasty Micro Catheters and ... shares and distribution shares data for each of these ...
(Date:12/5/2016)... 5, 2016  Cornerstone Pharmaceuticals, Inc., a privately ... from two Phase I trials evaluating its lead ... annual meeting of the American Society of Hematology ... . The two datasets show encouraging efficacy and ... (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), respectively, ...
Breaking Medicine Technology:
(Date:12/6/2016)... Sacramento, CA (PRWEB) , ... December 06, 2016 , ... ... travel can disrupt daily routines. That means it's also the season when eating healthy, ... those living with diabetes) on schedule is harder to do. , "Shopping trips, ...
(Date:12/6/2016)... ... December 06, 2016 , ... “Tatiana Sibirskaya: ... powerful woman's story of sacrifice and enlightenment. , “Tatiana Sibirskaya: A ... Fryer. Always looking for creative outlets, Carolyn gravitated toward writing through the inspiration ...
(Date:12/6/2016)... ... 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to ... give freedom to people who need help getting around. For some, advancing age has ... period of rehabilitation after an illness or accident. There is a wide variety of ...
(Date:12/6/2016)... California (PRWEB) , ... December 06, 2016 , ... "Add ... users to flicker, flash, and flare from clip to clip with high quality 4K ... , TransFlare 4K Jewel contains 44 lens flares filmed on the RED Dragon. Utilizing ...
(Date:12/5/2016)... ... , ... What: Shriners Hospitals for Children, with the help of Dimension Data, ... a video monitor and web-enabled camera. Santa visits with children through Dimension Data’s program ... Wonderland, which is where the video connection to the North Pole will stream. Much ...
Breaking Medicine News(10 mins):